Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 23, 2026, 8:37 PM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 23, 2026, 8:37 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects

NCT01133873
View directory record Official record
Conditions
Healthy
Interventions
Propoxyphene napsylate (XP20C), Placebo
Drug
Lead sponsor
Xanodyne Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

NCT03980041
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
Interventions
IPI-549 (eganelisib), Nivolumab, Placebos
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Fort Wayne, Indiana • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Placebo, topical testosterone, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 23, 2026, 8:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Multiple Platelet-Rich Plasma Lateral Epidondylitis Injections Versus a Single Platelet-Rich Plasma Injection

NCT02343822
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis
Interventions
Platelet Rich Plasma Injection, Saline Injection
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Modesto, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 4 Interventional Results available

Nebivolol in Patients With Systolic Stage 2 Hypertension

NCT01057251
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Foley, Alabama • Montgomery, Alabama • Chino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

NCT00971802
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-03882845 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

NCT01545453
View directory record Official record
Conditions
Asthma
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03895203
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 8:37 PM EDT
Suspended Phase 1 Interventional

Packed Red Blood Cell Transfusion During Cardiac Arrest

NCT06462027
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Packed Red Blood Cells (1 unit), Packed Red Blood Cells (2 units), Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of CK-1827452 Infusion in Stable Heart Failure

NCT00624442
View directory record Official record
Conditions
Heart Failure
Interventions
CK-1827452, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Diego, California • Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial Evaluating THB335 in Healthy Participants

NCT06425861
View directory record Official record
Conditions
Healthy
Interventions
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Drug
Lead sponsor
Third Harmonic Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

NCT02313454
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 23, 2026, 8:37 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854
View directory record Official record
Conditions
Alopecia
Interventions
Hair Stimulating Complex (HSC), Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

NCT00888745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
placebo, PRO283698
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
9
States / cities
Anniston, Alabama • Orlando, Florida • Ormond Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Not applicable Interventional Results available

Progel Vascular Sealant

NCT01959503
View directory record Official record
Conditions
Aortic Valve Stenosis, Aneurysm of Ascending Aorta, Aortic Valve Disorder, Bicuspid Valve Disorder
Interventions
Progel Vascular Sealant, Gelfoam Plus
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Wellness Behaviors as a Function of Oxytocin vs Placebo

NCT01929161
View directory record Official record
Conditions
Sustained Positive Emotions, Sustained Positive Behavior Change
Interventions
Oxytocin, Placebo (for oxytocin), Lovingkindness Meditation, Mindfulness Meditation
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
35 Years to 64 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

NCT01573442
View directory record Official record
Conditions
Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
Interventions
testosterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
528
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 1 Interventional

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

NCT01956305
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo, Metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 23, 2026, 8:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
View directory record Official record
Conditions
HIV Infections
Interventions
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

NCT00771953
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
apricoxib, Placebo, Docetaxel or Pemetrexed
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 23, 2026, 8:37 PM EDT